SCHEMBL7226885

SCHEMBL7226885

O=C(O)c1cc(F)cc2c1-c1c(cc(F)cc1[N+](=O)[O-])C2=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HKDC1 Q2TB90 1/20 0.48
TTR P02766 3/20 0.38
DTYMK P23919 1/20 0.38
S100A4 P26447 2/20 0.36
TSHR P16473 2/20 0.36
EIF4E P06730 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
TP53 P04637 2/20 0.35
CYP3A4 P08684 2/20 0.35
HIF1A Q16665 2/20 0.35
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CASP6 P55212 1/20 0.35
GPR35 Q9HC97 1/20 0.35
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
MAPK1 P28482 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4013929 0.86 TTR (0.45) TTRDTYMKTSHRCYP3A4CASP6
SCHEMBL7226887 0.83 HKDC1 (0.37) HKDC1TTRDTYMKS100A4TSHR
SCHEMBL10528832 0.81 HKDC1 (0.71) HKDC1TTRCYP3A4HIF1AHPGD
SCHEMBL9672294 0.77 HKDC1 (0.42) HKDC1S100A4TSHRTRPV1TP53
SCHEMBL912596 0.76 TTR (0.45) TTRDTYMKTSHRCYP3A4CASP6
SCHEMBL204106 0.74 TTR (0.55) TTRDTYMKTSHRTP53CYP3A4
SCHEMBL10530960 0.74 CASP6 (0.53) HKDC1TTRTSHRCYP3A4HIF1A
SCHEMBL21749958 0.74 CA1 (0.49) TTRDTYMKTSHRCASP6CYP1A2
SCHEMBL7234069 0.74 S100A4 (0.40) TTRS100A4TSHRTRPV1TP53
SCHEMBL4017658 0.73 AKR1C2 (0.44) TTRDTYMKTSHRHIF1ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6545011-B2 PARP (poly(adenosine 5'-diphospho-ribose) polymerase) inhibitors GUILFORD PHARMACEUTICALS INC. 2003-04-08 US disclosed
US-20020037904-A1 Substituted 4,9-dihydrocyclopent a [imn] phenanthridine-5-ones, derivatives thereof and their uses EISAI INC. 2002-03-28 US disclosed
WO-2002006240-A1 SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[IMN] PHENANTHRIDINE-5-ONES, DERIVATIVES THEREOF AND THEIR USES GUILFORD PHARMACEUTICALS INC. (US) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037904-A1 Substituted 4,9-dihydrocyclopent a [imn] phenanthridine-5-ones, derivatives thereof and their uses PARP1, PARP2, PARP4 HKDC1 1599/4885TTR 4884/4885DTYMK 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.